# The Effect of Alemtuzumab on the Blood-brain-barrier and the Brain's Metabolism in Multiple Sclerosis Patients

> **NCT03193086** · — · UNKNOWN · sponsor: **Glostrup University Hospital, Copenhagen** · enrollment: 35 (estimated)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Alemtuzumab

## Key facts

- **NCT ID:** NCT03193086
- **Lead sponsor:** Glostrup University Hospital, Copenhagen
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-01-01
- **Primary completion:** 2020-03-31
- **Final completion:** 2020-03-31
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2017-06-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03193086

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03193086, "The Effect of Alemtuzumab on the Blood-brain-barrier and the Brain's Metabolism in Multiple Sclerosis Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03193086. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*